Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;13(3):636-647.
doi: 10.1002/1878-0261.12440. Epub 2019 Feb 20.

Mission-oriented translational cancer research - health economics

Bengt Jönsson  1 , Richard Sullivan  2
Affiliations
Review

Mission-oriented translational cancer research - health economics

Bengt Jönsson et al. Mol Oncol. 2019 Mar.

Abstract

Health economics is an integrated aspect of all phases of mission-oriented translational cancer research and should be considered an intrinsic component of any study aimed at improving outcomes for patients and intervention costs. Information about value and value for money of new options for prevention and treatment is needed for decisions about their adoption and use by healthcare systems.

Keywords: cancer policy; cancer research; health economics; translational cancer research.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Disease burden of the top five disease groups in Europe 2000 and 2012. Source: World Health Organization (2014).
Figure 2
Figure 2
ICHOM standard set for outcome measurement in lung cancer. Source: ICHOM (2017).
Figure 3
Figure 3
Cost per life year gained from new cancer medicines. Figure reproduced from Howard et al. (2015). © American Economic Association; reproduced with permission of the Journal of Economic Perspectives.
Figure 4
Figure 4
Ranking and selecting new interventions in cancer based on cost per QALY gained.
Figure 5
Figure 5
Sales of oncology drugs per 100 000 inhabitants by time since launch by economic status of the country. Source: Jönsson et al. (2016b).
See this image and copyright information in PMC

References

    1. Aggarwal A, Fojo T, Chamberlain C, Davis C and Sullivan R (2017) Do patient access schemes for high‐cost cancer drugs deliver value to society? – Lessons from the NHS Cancer Drugs Fund. Ann Oncol 28, 1738–1750. - PMC - PubMed
    1. Davies A, Briggs A, Schneider J, Levy A, Ebeid O, Wagner S, Kotapati S and Ramsey S (2012) The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Res Med 3, e25–e36.
    1. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X et al (2013) Long‐term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor‐positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805–816. - PMC - PubMed
    1. Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A and Aggarwal A (2017) Availability of evidence on overall survival and quality of life benefits of cancer drugs approved by the European Medicines Agency: retrospective cohort study of drug approvals from 2009–2013. BMJ 359, j4530. - PMC - PubMed
    1. Eckhouse S, Lewis G and Sullivan R (2008) Trends in the global funding and activity of cancer research. Mol Oncol 2, 20–32. See also, Eckhouse S, Lewis G, Sullivan, R, 2006. A Survey of Public Funding of Cancer Research in the European Union. PLoS Med 3, e267. - PMC - PubMed

MeSH terms

Substances